Form 8-K

8-K — AIM ImmunoTech Inc.

Accession: 0001493152-26-036753

Filed: 2026-08-10

Period: 2026-08-07

CIK: 0000946644

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000946644

2026-08-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August

7, 2026

Aim Immunotech Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-27072

52-0845822

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2117

SW Highway 484, Ocala, FL

34473

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (352) 448-7797

Not Applicable

(Former name or former address,

if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol

Name

of each exchange on which registered

Common

Stock, $0.001 par value

AIM

NYSE

American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

Growth Company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02

Results

of Operations and Financial Condition.

August 10, 2026, AIM ImmunoTech Inc. (the “Company”) issued a press release (the “Press Release”) announcing

its financial results for the quarter ended June 30, 2026. A copy of the Press Release is attached to this Current Report on Form 8-K

as Exhibit 99.1 and, other than the quotes by Thomas Equels, is incorporated herein by reference.

The

information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for

purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections

11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall

not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by AIM ImmunoTech Inc.,

whether made before or after the date hereof regardless of any general incorporation language in such filing.

Item

9 .01

Financial

Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release, dated August 10, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

Date:

August 10, 2026

AIM

ImmunoTech Inc.

/s/

Thomas K. Equels

Thomas

K. Equels

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

CONFIDENTIAL

DRAFT NOT FOR IMMEDIATE RELEASE

AIM

ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward

Planned Phase 3 Development in Pancreatic Cancer

Completed

Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through

Early 2027

Pancreatic

Cancer Remains Strategic Priority as AIM Advances Toward Planned Phase 3 Development While Seeking Select Government-Funded Infectious

Disease Initiatives in Ebola

OCALA,

Fla., August 10, 2026 / AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported

financial results for the second quarter ended June 30, 2026, and provided a business update highlighting continued operational execution

across its lead pancreatic cancer program.

“AIM

continues to execute a clear and disciplined strategy centered on advancing Ampligen in pancreatic cancer,” said AIM Chief Executive

Officer Thomas K. Equels. “Over the past year, we have strengthened our financial position while completing enrollment and Ampligen

dosing in the metastatic pancreatic cancer Phase 2 clinical trial – critical steps as we move toward an anticipated Phase 3 study

in metastatic pancreatic cancer. We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold

standard data point in oncology – in Q3 2027. AIM expects that this data will amplify median Overall Survival findings from Ampligen’s

Dutch-government approved Named Patient Program in late-stage pancreatic cancer, where Ampligen achieved a median Overall Survival of

34.8 months compared to 12.5 months for historical controls – with favorable safety profile and high quality of life – in

a large, easily identifiable and key patient immune biomarker subset. This median improvement of 22.3 months will be a critical component

of the foundation for our pivotal Phase 3 clinical trial design in metastatic pancreatic cancer.”

Second

Quarter and Recent Operational Highlights

● Completed

patient enrollment and Ampligen dosing in the ongoing Phase 2 DURIPANC study evaluating

Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi®

(durvalumab) in metastatic pancreatic cancer.

● Engaged

Thermo Fisher Scientific’s PPD clinical research business to support study design

of a planned pivotal Phase 3 clinical trial in metastatic pancreatic cancer.

● Maintained

encouraging observations from Erasmus MC Cancer Institute, including favorable safety

findings, progression-free and overall survival trends, and consistently reported high quality

of life among treated patients.

● Strengthened

the Company’s balance sheet through multiple financing transactions, providing

additional resources to support continued clinical execution.

● Successfully

regained full compliance with NYSE American’s continued listing standards.

● Planning

government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola

virus disease, consistent with the Company’s strategy of pursuing non-dilutive

funding opportunities for select infectious disease programs while maintaining pancreatic

cancer as its primary strategic focus.

For

more information, please visit the Company’s website at aimimmuno.com.

Summary

of Financial Highlights for Second Quarter 2026

● As

of June 30, 2026, AIM reported $9.9 million in cash and cash equivalents, as compared to

approximately $3.0 million as of December 31, 2025.

● Research

and development expenses for the three months ended June 30, 2026 were approximately $589,000,

compared to $1.2 million during the same period in 2025.

● General

and administrative expenses were approximately $2.9 million for the second quarter of 2026,

compared to $1.5 million during the same period in 2025.

● Net

loss for the three months ended June 30, 2026 was approximately $(3.8 million), or $(0.43)

per share, compared to $(2.8 million), or $(3.68) per share, for the second quarter of 2025.

The

Company believes its strengthened financial position supports continued execution of its clinical development strategy and key upcoming

milestones. Please refer to the Company’s Form 10-Q for the quarter ended June 30, 2026, for complete financial results and additional

disclosures.

About

AIM ImmunoTech Inc.

AIM

ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),

for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective

TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by those sections.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied

by such forward-looking statements. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking

statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use

of words such as “believes,” “expects,” “intends,” “may,” “will,” “plans,”

“potential,” “anticipates,” “projects,” or the negative or plural of these words, or other similar

expressions that are predictions or indicate future events or prospects, but the absence of these words does not mean that a statement

is not forward-looking. Any forward-looking statements set forth in this press release speak only as of the date hereof. These forward-looking

statements are based upon the Company’s current expectations, estimates, assumptions, and beliefs concerning future events and

conditions, which are subject to change. Such forward-looking statements may include statements relating to: the anticipated timing of

DURIPANC study data, including clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027; anticipated survival outcomes,

quality-of-life measures, and the safety profile of Ampligen; the Company’s financial position to support clinical development

activities and key milestones; the pursuit of non-dilutive government funding opportunities for select infectious disease programs, including

the evaluation of Ampligen’s antiviral potential against Ebola virus disease; the Company’s Phase 3 clinical trial planning

efforts; the timing of commencement, enrollment, completion, and results of clinical trials; IP expansion and regulatory progress; and

timing for receiving government approvals, if at all. The Company does not undertake to update any of these forward-looking statements

to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various

stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and

immune-deficiency disorders, and disclosures in the Company’s reports filed with the U.S. Securities and Exchange Commission (the

“SEC”), on its website, and in its press releases set forth its current and anticipated future activities. These activities

are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen®

will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in

humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can

be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many

factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions

sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful

or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will

yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced

in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries

carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure

that its potential foreign operations will not be adversely affected by these risks.

For

a detailed discussion of risk factors that could cause actual results to differ materially from those described in the forward-looking

statements, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent

Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. The forward-looking statements in this press release

should be read in conjunction with such filings. These filings are available at www.sec.gov and www.aimimmuno.com. The information found

on the Company’s website is not incorporated by reference into this press release and is included for reference purposes only.

Investor

Contact:

JTC

Team, LLC

Jenene

Thomas

908.824.0775

AIM@jtcir.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (4413 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 07, 2026

Entity File Number

001-27072

Entity Registrant Name

Aim Immunotech Inc.

Entity Central Index Key

0000946644

Entity Tax Identification Number

52-0845822

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2117

SW Highway 484

Entity Address, City or Town

Ocala

Entity Address, State or Province

Entity Address, Postal Zip Code

34473

City Area Code

(352)

Local Phone Number

448-7797

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.001 par value

Trading Symbol

AIM

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration